Affineti Biologics has received a commitment of up to $500,000 from Foundation Venture Capital Group (FVCG) to advance its research in the development of therapeutic and diagnostic products based on new discoveries in oral biology and dental medicine.
The company invested in Affineti because positive results from studies for anticaries and periodontal therapy look promising in their ability to affect plaque reduction, influencing dental hygiene and systemic medicine, noted James Golubieski, president of FVCG.
Affineti uses biological principals to create hybrid or fusion proteins that adhere to tissues with potent but nontoxic antimicrobial effects, according to FVCG. Researchers hope to use these proteins to deliver effective substances locally, avoiding systemic complications. In the short term, Affineti plans to use these proteins in conditions related to the oral cavity, then expanding to include mucosal infections in other sites throughout the body.
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
